Ranbaxy Laboratories has initiated phase I clinical trial of a lead compound for respiratory inflammation, a company release said today.
This is part of a joint collaborative programme with GlaxoSmithKline.
The company added that the trials will be conducted in India and Europe.
The release further added that Ranbaxy will receive a milestone payment for initiating the phase I studies and will also be responsible for conducting phase II clinical studies.